Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems (Hybrid CATT1)

November 6, 2026 updated by: vTv Therapeutics

Hybrid CATT1: Hybrid Closed Loop Insulin Pumps With Cadisegliatin as Adjunctive Treatment in Patients With Type 1 Diabetes A Phase 2a Double Blind Randomized Cross-Over Study

TTP399-206 is a Phase 2a multicenter double blind cross over randomized study of cadisegliatin in participants with T1D using hybrid closed loop systems to manage their diabetes. Participants using a hybrid closed loop insulin pump to manage their diabetes will be randomized to either receive blinded cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment or placebo QD along with their insulin treatment. The trial begins with a screening period of up to 2 weeks, followed by a device training and insulin adjustment period of 1-2 weeks leading into the first double-blind treatment period of 6 weeks. There will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participants will cross-over to the treatment that they did not receive in the first treatment period.

Study Overview

Status

Recruiting

Detailed Description

TTP399-206 is a 20 week, Phase 2a trial designed to evaluate efficacy and safety of cadisegliatin in participants with T1D who are using hybrid closed loop (HCL) systems to manage their condition to gather preliminary data to understand how cadisegliatin performs in an HCL setting.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • California
      • Modesto, California, United States, 95355
        • Recruiting
        • Paradigm Clinical Research -Modesto
        • Principal Investigator:
          • Gopika Gangupantula, MD
      • San Diego, California, United States, 92108
        • Recruiting
        • Paradigm Clinical Research Centers, LLC
        • Principal Investigator:
          • Schafer Boeder, MD
    • Colorado
      • Aurora, Colorado, United States, 80045
        • Recruiting
        • Barbara Davis Center for Diabetes
        • Principal Investigator:
          • Halis Kaan Akturk, MD
    • Georgia
      • Atlanta, Georgia, United States, 30318
        • Recruiting
        • Atlanta Diabetes Associates
        • Principal Investigator:
          • Bruce W Bode, MD
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27514
        • Recruiting
        • UNC Eastowne Medical Office Building
        • Principal Investigator:
          • Klara Klein, MD, PhD
    • Texas
      • Austin, Texas, United States, 78731
        • Recruiting
        • Texas Diabetes & Endocrinology, P.A.
        • Principal Investigator:
          • Thomas Blevins, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Key Inclusion Criteria:

  • Participants >= 18 years of age
  • Fasting C-peptide levels <0.6 ng/ml
  • Average TIR < 70% recorded on their personal CGM data collected over the past 7 days prior to Visit 1
  • Currently on a hybrid closed loop device for at least 3 months and willing to stay on the same model of pump device for study duration
  • Willing to wear a study provided CGM for study duration
  • Total bilirubin ≤2×ULN, ALT and AST ≤3×ULN

Key Exclusion Criteria:

  • Have Type 2 Diabetes Mellitus (DM), monogenic diabetes, maturity-onset diabetes, other unusual or rare forms of DM, or diabetes resulting from a secondary disease.
  • Have been hospitalized for DKA within 3 months
  • Have uncontrolled hypothyroidism or hyperthyroidism
  • Have QTcF interval > 450 msec for males or > 470 msec for females
  • Have a personal or family history of long QT syndrome, Torsades de pointes, or other complex ventricular arrhythmias
  • Have persistent, uncontrolled hypertension
  • Have clinically significant cardiovascular or cerebrovascular disease
  • Have proliferative retinopathy or maculopathy requiring acute treatment
  • Have a serious concomitant systemic disorder including but not limited to HIV or active Hep B or Hep C
  • Have been diagnosed and/or treated for malignancy within 3 years
  • Have used any of the following medications within the specified time periods: any non-insulin anti-diabetic therapies (e.g.SGLT-2 inhibitors, GLP-1 receptor agonists, metformin, sulfonylureas, DPP-4 inhibitors, pramlintide, a-glucosidase inhibitors, or glucose dependent insulinotropic polypeptide agonists) within 30 days, antipsychotic medications (e.g. olanzapine, risperidone, clozapine, quetiapine, and haloperidol) within 30 days, systemic corticosteroids for ≥7 days for a temporary medical condition within 30 days,

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cadisegliatin 800 mg QD, then Placebo

If a participant is randomized to receive cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment in the first double-blind treatment period of 6 weeks, there will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participant will cross-over to the placebo QD along with their insulin treatment

Cadisegliatin is an orally bioavailable small-molecule glucokinase activator, adjunctive therapy to insulin

Other Names:
  • TTP399

Placebo (insulin alone)

Experimental: Placebo, then Cadisegliatin 800 mg QD

If a participant is randomized to receive placebo QD along with their insulin treatment in the first double-blind treatment period of 6 weeks, there will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participant will cross-over to the cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment

Cadisegliatin is an orally bioavailable small-molecule glucokinase activator, adjunctive therapy to insulin

Other Names:
  • TTP399

Placebo (insulin alone)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To assess the change in Time in Range (TIR)
Time Frame: last 2 weeks of the two 6-week treatment periods

Time in Range (TIR) based on study CGM in participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo

last 2 weeks of the two 6-week treatment periods

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
CGM-based metric for glycemic control
Time Frame: last 2 weeks of each treatment period

Time In Tight Range (TITR)

last 2 weeks of each treatment period
CGM-based metric for glycemic control
Time Frame: last 2 weeks of each treatment period

Time Above Range (TAR)

last 2 weeks of each treatment period
CGM-based metric for glycemic control
Time Frame: last 2 weeks of each treatment period

Time Below Range (TBR)

last 2 weeks of each treatment period
CGM-based metric for glycemic control
Time Frame: last 2 weeks of each treatment period

Glucose Management Indicator (GMI)

last 2 weeks of each treatment period
CGM-based metric for glycemic control
Time Frame: last 2 weeks of each treatment period

Glucose variability (GV)

last 2 weeks of each treatment period
CGM-based metric for glycemic control
Time Frame: last 2 weeks of each treatment period

Time in Range (TIR) > 70%

last 2 weeks of each treatment period
Change in glucose control after standardized mixed meal tolerance test (MMTT)
Time Frame: 12 weeks

Glucose Peak Plasma Concentration (Cmax) based on study CGM after standardized mixed meal tolerance test (MMTT)

12 weeks
Change in glucose control after standardized mixed meal tolerance test (MMTT)
Time Frame: 12 weeks

Glucose Area under the plasma concentration versus time curve (AUC) based on study CGM after standardized mixed meal tolerance test (MMTT)

12 weeks
To assess the change in Level 1, Level 2 , and Level 3 hypoglycemic incidence
Time Frame: 12 weeks

Number of events of Level 1 and Level 2 hypoglycemia as determined by CGM and Level 3 hypoglycemic events in participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo

12 weeks
Assess incidence of Serious Adverse Events (SAEs)
Time Frame: 14 weeks

Number of Serious Adverse Events (SAEs)

14 weeks
Assess incidence of Treatment Emergent Adverse Events (TEAEs)
Time Frame: 14 weeks

Number of treatment emergent adverse events (TEAEs)

14 weeks
Assess incidence of Treatment Emergent Adverse Events (TEAEs) leading to discontinuation
Time Frame: 14 weeks

Number of treatment emergent adverse events (TEAEs) leading to discontinuation of study drug

14 weeks
Assess incidence of Adverse Events of Special Interest (AESIs)
Time Frame: 14 weeks

Number of adverse events of special interest (AESIs)

14 weeks
Change from baseline in average daily total insulin dose
Time Frame: last week of the two 6-week treatment periods

Change from baseline in average daily total insulin dose in units (IU) based on manual entry in eDiary records from participants with T1D who are using hybrid closed loop systems on cadisegliatin vs placebo

last week of the two 6-week treatment periods

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Maria Alba, MD, vTv Therapeutics LLC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 29, 2026

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

May 15, 2026

First Submitted That Met QC Criteria

May 22, 2026

First Posted (Actual)

June 1, 2026

Study Record Updates

Last Update Posted (Actual)

November 10, 2026

Last Update Submitted That Met QC Criteria

November 6, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe